Study validating economic advantages of PTRA test

AI SummaryClose X

Verici Dx Plc announced the publication of a health economic study in the Journal of Health Economics and Outcomes Research, which demonstrates the significant potential cost benefits of its Pre-Transplant Risk Assessment (PTRA) test for predicting early acute rejection in kidney transplants. The study, conducted by Avalon Health Economics, indicates that integrating the PTRA test into standard clinical practice could lead to over $191 million in healthcare savings across the U.S. standard-risk kidney transplant population over two years by enabling more personalized immunosuppression strategies, potentially reducing adverse events and unfavorable clinical outcomes.

Disclaimer*

Companies

Verici DX (VRCI)
UK 100

Latest directors dealings